CDT Equity Inc. CDT
CDT Equity Inc. (Nasdaq: CDT) is an immunology/inflammation drug developer. Its lead program, AZD1656 co-crystal (HK-4 glucokinase activator), is in Pre-clinical for inflammatory/autoimmune disorders (repurposing, AI-guided).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AZD1656 co-crystal | autoimmune/inflammatory disorders | small molecule | Pre-clinical |
| Idiopathic male infertility candidate | idiopathic male infertility | small molecule | Pre-clinical |
| Dermatology and animal health candidates (via Manoira) | dermatology; veterinary | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.